To minimize patient exposure and preserve hospital resources during the COVID-19 pandemic, hospitals across the US were asked to sharply decrease the volume of nonurgent surgical cases, including oncologic procedures. The COVID-19 Pandemic Breast Cancer Consortium released recommendations about prioritization of breast cancer operations to aid decision-making, with the recognition that few prospective data existed on the repercussions of the suggested strategies.[@bib1] It was recommended that operations for ductal carcinoma in situ (DCIS) be deferred until after resolution of the pandemic, with suggested initiation of neoadjuvant endocrine therapy (NET) in patients with estrogen receptor-positive (ER+) DCIS. NET was similarly recommended as the preferred strategy for patients with early-stage ER+ invasive breast cancer.

The impact of time to operation on breast cancer outcomes in these very-early-stage patients remains unclear. Time to operation has been shown to be associated with increase in upstaging from DCIS to invasive disease on the order of 1% per month, but with excellent survival rates even in upstaged patients.[@bib2] In invasive cancer patients, studies using nodal positivity as a surrogate outcomes measure have demonstrated mixed results.[@bib3] ^,^ [@bib4] In addition, survival analyses have similarly reported varied findings, leaving surgeons without a clear sense of the repercussions that can result from treatment delays.

NET use has primarily been used in patients with stage II and III ER+ disease, demonstrating tumor responses comparable with those seen with neoadjuvant chemotherapy.[@bib5] ^,^ [@bib6] Survival data in NET patients are more difficult to interpret, not only because of the long disease-free intervals associated with ER+ disease, but also because adjuvant treatment pathways are not standardized in NET patients.[@bib5] ^,^ [@bib7] There are definitive data in older adults with ER+ disease that demonstrate no overall survival (OS) difference between primary endocrine therapy alone vs operation plus endocrine therapy.[@bib8], [@bib9], [@bib10] Use of NET as a delay strategy during the pandemic in patients with early-stage ER+ disease has a basis in high-quality evidence, but given the historical selection bias for NET in postmenopausal patients, it does to a certain extent represent an extrapolation of existing data to a broader population.

The true oncologic ramifications of these delay strategies will be observed over time. Understanding the possible outcomes earlier, however, could be useful in effectively counseling and reassuring patients about surgical delays and the broadened use of NET. Our primary objective was to understand the possible effects of COVID-related surgical delays on breast oncology outcomes by examining the association between time to operation and pathologic staging, with secondary analyses evaluating OS and extent of breast operation.

Methods {#sec1}
=======

Data from 2010 through 2016 were abstracted from the participant user file of the National Cancer Database (NCDB). The NCDB is an oncology dataset that captures approximately 70% of newly diagnosed cancer in the US.[@bib1] It is a joint project of the American Cancer Society and the Commission on Cancer of the American College of Surgeons, receiving data from approximately 1,500 Commission on Cancer-accredited cancer programs. This study was deemed exempt from review by the Brigham and Women's Hospital IRB.

Patients {#sec1.1}
--------

All patients diagnosed January 1, 2010 through December 31, 2016 who underwent breast cancer operations were identified. Given recommendations of the COVID-19 Pandemic Breast Cancer Consortium, the population of interest was patients with DCIS or early-stage (cT1-2N0) ER+ disease.[@bib1] Patients who were treated outside the reporting facility, had unknown ER status, unknown surgical timing, unknown surgical pathology data, or who underwent more than 1 operation were excluded. In addition, patients who did not undergo operation within 1 year of diagnosis, who received neoadjuvant chemotherapy, or, in the case of patients with invasive disease, those who did not receive endocrine therapy at all were excluded. An exceedingly small number of patients with DCIS received NET, precluding reliable analysis of this subpopulation, and were excluded. The remaining 99,749 DCIS patients, 222,933 cT1N0, and 56,157 cT2N0 patients were assessed ([Fig. 1](#fig1){ref-type="fig"} ).Figure 1Consolidated Standards of Reporting Trials diagram. ER, estrogen receptor; NCDB, National Cancer Database; NET, neoadjuvant endocrine therapy.

Variables {#sec1.2}
---------

The exposure of interest was time to operation from time of diagnosis, originally defined as 30 or fewer days, 31 to 60 days, 61 to 90 days, 91 to 120 days, and more than 120 days. As outcomes of interest did not significantly vary from 0 to 30 vs 30 to 60 days or from 60 to 90 vs 90 to 120 days, these categories were collapsed into 60 or fewer days, 61 to 120 days, and more than 120 days. Patient-level variables included age (18 to 39 years, 40 to 49 years, 50 to 59 years, 60 to 69 years, 70 to 79 years, and older than 80 years), race/ethnicity (white, black, Hispanic, Asian, and other/unknown), insurance status (private, Medicare, Medicaid, uninsured, and other/unknown), regional location of the patient's home ZIP code (metropolitan, urban, or rural). Disease characteristics included tumor grade (classified as 1, 2, or 3) and tumor histology (ductal, lobular, or mixed). Both clinical and pathologic tumor category (Tis, T1, T2, T3, or T4) and nodal category (Nx, N0, N1, N2, or N3) were included. Treatment characteristics included operation type (breast-conserving surgery \[BCS\] vs mastectomy), radiation therapy (yes/no), and adjuvant chemotherapy (yes/no). Facility type was also incorporated, defined by Commission on Cancer accreditation status as a community cancer program, comprehensive community cancer program, academic/research program, or integrated network cancer program.

Outcomes measures {#sec1.3}
-----------------

The main measure of interest was the proportion of DCIS, cT1N0, and cT2N0 patients who were upstaged on final surgical pathology. Inclusion criteria were based on T and N categories, and the outcomes measure was based on the 8^th^ edition of the American Joint Committee on Cancer's *AJCC Cancer Staging Manual*.[@bib11] Patients included in the cT1N0 and cT2N0 groups were recoded by the 8^th^ edition clinical prognostic staging criteria and were deemed "upstaged" if their pathologic prognostic stage was higher than their clinical prognostic stage. Secondary outcomes measures were 5-year OS and type of breast procedure (BCS vs mastectomy).

Statistical analysis {#sec1.4}
--------------------

Time to operation was treated as a categorical variable, defined by the date of diagnosis to the date of operation. All tests were 2-sided with a p value \< 0.05 considered statistically significant. Analyses were stratified by clinical staging on presentation (DCIS, cT1N0, cT2N0); all DCIS patients (ER+ and ER--) underwent upfront operation, and the cT1N0 and cT2N0 groups were also stratified by initial treatment strategy (NET vs primary operation). Chi-square tests of proportion were performed to test the significance of baseline differences in the study population. Univariable logistic regression models were used to examine factors associated with pathologic upstaging ([eTable 1](#appsec1){ref-type="sec"}). To test the significance of time to operation controlled for all other patient and hospital covariates, a multivariable analysis was performed using a random intercept, fixed slope, logistic regression model with the hospital as a random effect. Variables for this model were chosen a priori, and included age, race, Charlson Comorbidity Index score, insurance status, facility type, tumor histology, operation type, and time to operation. Tumor grade was not included in this model, given that it is a significant part of the 8^th^ edition prognostic pathologic staging system (ie the outcomes variable). A multivariable logistic regression model was also performed to determine significant factors associated with receipt of NET. Cox proportional hazards models---adjusted for age, race, comorbidity index, tumor grade, histology, operation type, pathologic tumor and nodal category, and adjuvant therapy (chemotherapy and radiation therapy)---were used to compare OS by time from diagnosis to operation by clinical disease stage (DCIS, cT1N0, cT2N0), and initial treatment strategy (NET vs primary operation). All analyses were performed using SPSS, version 19.0 (IBM Corp).

Results {#sec2}
=======

Of the 99,749 DCIS patients, 83,754 (84%) had ER+ disease and 15,995 (16%) had ER-- disease. Of the patients with cT1N0 disease, 1,591 (0.7%) underwent NET and the remaining underwent primary operation. A greater percentage of patients (3.3%) with cT2N0 disease underwent NET (n = 1,880). For patients with cT1-2N0 disease, multivariable analysis showed that older age, higher comorbidity index (Charlson Comorbidity Index score ≥ 3: odds ratio \[OR\] 1.83; 95% CI, 1.41 to 2.39 \[reference: Charlson Comorbidity Index of 0\]), lobular disease (OR 1.17; 95% CI, 1.06 to 1.29), and cT2 vs cT1 tumor (OR 5.40; 95% CI, 5.01 to 5.81) were among the factors significantly associated with NET receipt ([eTable 2](#appsec1){ref-type="sec"}).

Clinicopathologic characteristics of the patients in each group are shown in [Table 1](#tbl1){ref-type="table"} . In the DCIS group, 98.2% of patients underwent operations in the first 120 days. Similarly, 99.4% of cT1N0 patients and 99.1% of cT2N0 patients in the primary operation group underwent operation within 120 days. In contrast, 59.6% of the cT1N0 and 30.9% of the cT2N0 NET patients underwent operations within 120 days.Table 1Patient CharacteristicsCharacteristicDCIS patientcT1N0 patientcT2N0 patientER+ (n = 83,754)ER-- (n = 15,995)NET (n = 1,591)Primary operation (n = 221,342)NET (n = 1,880)Primary operation (n = 54,277)n%n%n%n%n%n%Age[∗](#tbl1fnlowast){ref-type="table-fn"} 18--39 y2,4512.95073.2291.84,8182.2211.12,6714.9 40--49 y17,15020.52,33114.617010.730,43213.71578.49,82718.1 50--59 y23,59328.24,66129.133621.155,48525.136219.313,32724.6 60--69 y23,97228.648,89030.649230.972,23932.658130.914,62126.9 70--79 y13,04515.62,65716.635722.445,17420.444923.99,22317.0 80 y or older3,5434.29495.920713.013,1946.031016.54,6088.5Race[∗](#tbl1fnlowast){ref-type="table-fn"} White63,65976.012,55178.51,32283.1186,58784.31,49179.343,62880.4 Black10,66512.71,64310.31197.516,2547.31719.14,8298.9 Hispanic5,0736.19475.9935.810,2784.61377.33,2326.0 Asian3,8594.67674.8473.06,9613.1703.72,2404.1 Other4980.6870.5100.61,2620.6110.63480.6Comorbidity index 070,82484.613,51484.51,23477.6184,37383.31,53981.944,44681.9 110,51912.61,98212.423915.029,63613.424112.87,75714.3 21,8532.23912.4784.95,5492.5683.61,5242.8 ≥ 35580.71080.7402.51,7840.8321.75501.0Insurance[∗](#tbl1fnlowast){ref-type="table-fn"} Private50,75460.69,19357.566341.7117,86553.371337.929,02153.5 Medicare25,77830.85,42633.975647.586,47539.195350.719,43135.8 Medicaid4,2285.07894.91026.410,0994.61206.43,6796.8 Other government9311.11671.0120.82,2331.0201.15771.1 Uninsured1,2251.52601.6271.72,6031.2432.31,0161.9 Unknown8381.01601.0311.92,0670.9311.65531.0Region Metro70,85884.613,42283.91,29681.5182,50482.51,57183.644,63382.2 Urban9,55811.41,90211.921813.729,28113.222612.07,37213.6 Rural1,2141.42571.6332.13,9171.8291.59621.8 Unknown2,1242.54142.6442.85,6402.5542.91,3102.4Facility type[∗](#tbl1fnlowast){ref-type="table-fn"} Community6,4658.01,1837.61127.219,2788.91327.14,7579.2 Comprehensive36,64445.17,17646.362339.998,29045.471738.623,67145.9 Academic25,20631.04,67430.252433.566,49130.770437.915,66230.3 Integrated network12,98816.02,45515.930319.432,46515.030616.57,51614.6Histology[∗](#tbl1fnlowast){ref-type="table-fn"} DuctalNANANANA1,21976.6176,97280.01,28468.339,90573.5 LobularNANANANA19912.522,19210.034918.68,32215.3 MixedNANANANA17310.922,17810.024713.16,05011.1Grade[∗](#tbl1fnlowast){ref-type="table-fn"} 111,31413.52631.659127.177,87835.249826.58,97116.5 233,31139.82,14913.480550.6109,10849.31,04055.328,76253.0 326,25731.410,90368.21247.825,83711.726714.214,52926.8 Unknown12,87215.42,68016.8714.58,5193.8754.02,0153.7Operative time from diagnosis \< 60 d69,53983.013,19782.535222.1199,77890.31377.347,59887.7 61--120 d12,68915.22,50415.759637.520,2089.144423.66,18711.4 \> 120 d1,5261.82941.864340.41,3560.61,29969.14920.9Operation type[∗](#tbl1fnlowast){ref-type="table-fn"} BCS60,12071.89,40258.81,08568.2170,93377.21,17362.426,80349.4 Mastectomy23,63428.26,59341.250631.850,40922.870737.627,47450.6Axillary operation type[∗](#tbl1fnlowast){ref-type="table-fn"} None36,69143.84,70429.416810.65,38259.31869.91,1742.2 SLNB22,36026.75,76636.091657.6131,30611.595250.625,78347.5 SLNB/ALND3,3534.06764.218411.625,43111.529215.510,51419.4 ALND2,6493.29586.01036.512,4865.61306.94,5198.3 Unknown18,70122.33,89124.322013.846,73721.132017.012,28722.6pT[∗](#tbl1fnlowast){ref-type="table-fn"} pT075,07589.613,19282.5372.36600.3170.9550.1 pT18,2469.82,61916.41,30882.2197,25289.168436.410,64119.6 pT23510.41510.922414.12,21610.01,06456.640,93975.4 pT3610.1260.2201.31,0800.5955.12,4294.5 pT4110.070.020.11340.1201.12130.4pN[∗](#tbl1fnlowast){ref-type="table-fn"} pN058,32869.612,53978.41,18274.3184,29383.31,13860.534,65363.8 pN18401.02851.824715.530,12913.650126.615,30128.2 pN2640.1390.2211.32,4221.1603.22,6174.8 pN3370.0120.190.66950.3301.68861.6 pNx24,48529.23,12019.51328.33,8031.71518.08201.5Adjuvant treatment Endocrine therapy[∗](#tbl1fnlowast){ref-type="table-fn"}43,87352.49796.11,591100221,3421001,88010054,277100 Chemotherapy[∗](#tbl1fnlowast){ref-type="table-fn"}1,7672.11,1777.417711.139,74918.028415.623,13942.6 Radiation[∗](#tbl1fnlowast){ref-type="table-fn"}45,56554.48,15751.084953.4161,32872.91,05256.0326,68060.2[^1][^2]

Among DCIS patients, mastectomy was more common in ER-- than ER+ disease (41.2% vs 28.2%; p \< 0.01). Among cT1N0 patients, mastectomy was more common in the NET group (31.8%) than in the primary operation group (22.8%) (p \< 0.01), and in cT2N0 patients, BCS rates were higher in the NET group compared with the primary operation group (62.4% vs 49.4% respectively; p \< 0.01).

Association between time to operation and pathologic upstaging {#sec2.1}
--------------------------------------------------------------

In total, a greater proportion of patients with ER-- DCIS (17.6%) were upstaged to invasive disease compared with patients with ER+ DCIS (10.4%) ([Table 2](#tbl2){ref-type="table"} ). The proportion of patients who were upstaged on final pathology increased by time to operation among both the ER+ and ER-- DCIS patients ([Fig. 2](#fig2){ref-type="fig"} ; p \< 0.001 for both). A small group of patients (\< 5%) had invasive disease on final pathology but were missing elements (eg grade or nodal status) needed to accurately stage them per the 8^th^ edition prognostic pathologic staging criteria, and were coded as being upstaged, yet "unknown." Among the statistically significant factors associated with pathologic upstaging among ER+ DCIS patients on adjusted analysis was time to operation, as patients undergoing operations more than 60 days after diagnosis had an OR of 1.15 (95% CI, 1.08 to 1.22) compared with those who underwent operations within the first 60 days ([Table 3](#tbl3){ref-type="table"} ). Patients with ER-- DCIS also had higher odds of being upstaged, but only if they underwent operations more than 120 days after diagnosis (OR 1.36; 95% CI, 1.01 to 1.82). Patients with both ER+ and ER-- DCIS undergoing mastectomy were more likely to be upstaged than those undergoing BCS (ER+: OR 2.76; 95% CI, 2.63 to 2.90; ER--: OR 2.14; 95% CI, 1.96 to 2.35).Table 2Patient Population by TNM Stage/Primary Treatment, American Joint Committee on Cancer 8^th^ Edition Clinical Prognostic Staging and 8^th^ Edition Pathologic Prognostic StagingCancer type, AJCC 8^th^ edition clinical prognostic stage, pathologic prognostic stagen%Pathologic upstagingER+ DCIS (n = 83,754) 0 075,02489.6Same stage IA5,5616.6Upstage IB2520.3Upstage IIA-B1620.4Upstage IIIA-C460.0Upstage Unknown2,7093.2UpstageER-- DCIS (n = 15,995) 0 013,17582.4Same stage IA9225.8Upstage IB5903.6Upstage IIA-B2981.9Upstage IIIA-C810.5Upstage Unknown1,9265.8UpstagecT1N0 NET (n = 1,395) IA1,37598.6--- 0302.2Downstage IA1,22288.9Same stage IB795.7Upstage IIA-B332.4Upstage IIIA-C110.8Upstage IB201.4--- 000Downstage IA840.0Downstage IB00Same stage IIA-B1155.0Upstage IIIA-C15.0UpstagecT1N0 upfront operation (n = 209,102) IA204,94498.0--- 05870.3Downstage IA189,15992.3Same stage IB10,7405.2Upstage IIA-B2,7761.7Upstage IIIA-C8880.4Upstage IB4,1582.0--- 0110.3Downstage IA2,91770.2Downstage IB00Same stage IIA-B1,12527.1Upstage IIIA-C1062.5UpstagecT2N0 NET (n = 1,649) IB1,28878.1--- 0110.9Downstage IA1,01979.1Downstage IB22917.8Same stage IIA-B00Upstage IIIA-C292.3Upstage IIA33220.1--- 020.6Downstage IA8826.5Downstage IB11634.9Downstage IIA7923.8Same stage IIB309.0Upstage IIIA-C175.1Upstage IIB291.8--- 000Downstage IA827.6Downstage IB00Downstage IIA1137.9Downstage IIB724.1Same stage IIIA-C310.3UpstagecT2N0 upfront operation (n = 51,208) IB33,64865.7--- 0390.1Downstage IA24,92974.1Downstage IB8,06124.0Same stage IIA-B00Upstage IIIA-C6191.8Upstage IIA14,83129.0--- 060.0Downstage IA1,99713.5Downstage IB6,45443.5Downstage IIA4,39629.6Same stage IIB1,4129.5Upstage IIIA-C5663.9Upstage IIB2,7295.3--- 040.1Downstage IA2851.0Downstage IB00Downstage IIA1,74664.0Downstage IIB52019.1Same stage IIIA-C1746.4Upstage[^3]Figure 2Change in American Joint Committee on Cancer 8th edition pathologic prognostic stage by time to operation, stratified by disease subtype and initial treatment strategy; time to operation in days. DCIS, ductal carcinoma in situ; ER, estrogen receptor; NET, neoadjuvant endocrine therapy.Table 3Multivariable Analysis of Factors Associated with Upgrade by the American Joint Committee on Cancer 8^th^ Edition Prognostic StagingPatient characteristicER+ DCISER-- DCISNETPrimary operationOR (95% CI)p ValueOR (95% CI)p ValueOR (95% CI)p ValueOR (95% CI)p ValueAge 18--39 yToo few events---Too few events---Too few events---Too few events--- 40--49 y1Ref1Ref1Ref1Ref 50--59 y1.00 (0.94--1.07)0.99(0.77 0.68--0.87)\< 0.01(0.84 0.50--01.40)0.50(1.00 0.96--1.05)0.90 60--69 y1.05 (0.98--1.13)0.19(0.67 0.59--0.78)\< 0.01(0.61 0.35--1.06)0.08(0.87 0.83--0.92)\< 0.01 70--79 y1.14 (1.03--1.25)0.01(0.64 0.53--0.78)\< 0.01(0.81 0.44--1.51)0.51(0.84 0.79--0.89)\< 0.01 80 y or older1.32 (1.15--1.51)\< 0.01(0.61 0.47--0.78)\< 0.01(1.56 0.82--2.98)0.17(1.22 1.13--1.32)\< 0.01Race White1Ref1Ref1Ref1Ref Black0.98 (0.91--1.05)0.49(1.26 1.10--1.45)\< 0.01(1.27 0.78--2.10)0.34(1.46 1.38--1.53)\< 0.01 Hispanic1.12 (1.01--1.24)0.03(1.08 0.89--1.30)0.45(1.19 0.65--2.18)0.58(1.19 1.11--1.27)\< 0.01 Asian1.22 (1.09--1.36)\< 0.01(1.41 1.15--1.71)\< 0.01(0.92 0.39--2.18)0.85(0.93 0.85--1.01)0.10Comorbidity index 01Ref1Ref1Ref1Ref 11.13 (1.05--1.21)\< 0.01(1.13 0.99--1.29)0.06(0.94 0.60--1.45)0.76(1.05 1.01--1.10)00.02 21.33 (1.14--1.54)\< 0.01(1.27 0.97--1.67)0.08(1.21 0.62--2.38)0.58(1.13 1.03--1.24)0.01 ≥ 31.36 (1.05--1.76)0.02(1.26 0.73--2.16)0.40(1.92 0.85--4.31)0.11(1.12 0.95--1.31)0.18Insurance Private1Ref1Ref1Ref1Ref Medicare0.93 (0.87--0.99)0.040.93 0.81--1.06)0.27(1.54 0.99--2.37)0.06(0.98 0.93--1.02)0.31 Medicaid1.06 (0.95--1.18)0.281.30 1.08--1.57)0.01(1.69 0.97--2.95)0.06(1.27 1.19--1.36)\< 0.01 Uninsured0.90 (0.74--1.09)0.280.84 0.60--1.18)0.31(0.55 0.12--2.44)0.43(1.28 1.13--1.44)\< 0.01Facility type Community1Ref1Ref1Ref1Ref Comprehensive1.26 (1.14--1.38)\< 0.01(1.26 1.05--1.52)\< 0.01(1.60 0.80--3.20)0.18(0.96 0.91--1.02)0.17 Academic1.53 (1.38--1.69)\< 0.01(1.81 1.49--2.19)\< 0.01(1.81 0.91--3.63)0.09(0.96 0.90--1.02)0.15 Integrated network1.29 (1.15--1.44)\< 0.01(1.54 1.25--1.89)\< 0.01(1.64 0.79--3.44)0.19(0.91 0.86--0.97)0.01Histology Ductal1Ref1Ref1Ref1Ref LobularNA---NA---(1.75 1.21--2.53)\< 0.01(1.50 1.44--1.57)\< 0.01 Mixed0.13 (0.12--0.14)\< 0.01(0.08 0.06--0.10)\< 0.01(1.25 0.80--1.96)0.32(1.13 1.08--1.19)\< 0.01cT cT1NA all cTis---------1Ref1Ref cT2------------(0.36 0.26--0.50)\< 0.01(0.47 0.45--0.49)\< 0.01Operation type BCS1Ref1Ref1Ref1Ref Mastectomy2.76 (2.63--2.90)\< 0.01(2.14 1.96--2.35)\< 0.01(3.07 2.26--4.17)\< 0.01(2.82 2.73--2.91)\< 0.01Operation timing \<60 d1Ref1Ref1Ref1Ref 60--120 d1.15 (1.08--1.22)\< 0.01(1.09 0.97--1.23)0.14(1.01 0.64--1.61)0.96(0.92 0.88--0.97)\< 0.01 \> 120 d1.44 (1.24--1.68)\< 0.01(1.36 1.01--1.82)0.04(1.46 0.94--2.29)0.09(1.06 0.90--1.25)0.48[^4]

In total, a larger proportion of T1N0 NET patients (9.7%) were upstaged compared with the T2N0 NET patients (4.8%) ([Table 2](#tbl2){ref-type="table"}). The proportion of patients who were upstaged on final pathology increased by time to operation among the T1N0 NET patients (p \< 0.03), but not the T2N0 NET patients (p = 0.455) ([Fig. 2](#fig2){ref-type="fig"}). Of the cT2N0 NET patients, 80% of those with clinical stage IB disease, 62% of those with stage IIA disease, and 65.5% of those with stage IIB disease were downstaged on final pathology. On adjusted analysis, NET patients undergoing operations more than 60 days after diagnosis were not more likely to be upstaged on final pathology compared with those undergoing operations in 60 or fewer days ([Table 3](#tbl3){ref-type="table"}). Patients with lobular disease were more likely to be upstaged (OR 1.75; 95% CI, 1.21 to 2.53) compared with those with ductal or mixed histologies. NET patients undergoing mastectomy also had higher odds of upstaging on final pathology (OR 3.07; 95% CI, 2.26 to 4.17), although those who were initially staged as having cT2 disease compared with those with cT1 disease were less likely to be upstaged (OR 0.36; 95% CI, 0.26 to 1.47).

Among primary operation patients, 7.5% of cT1N0 patients and 5.4% of cT2N0 patients were upstaged on final pathology. The proportion of patients who were upstaged increased by time to operation (cT1N0: 7.7% in the fewer than 60 days group compared with 11.1% in the more than 120 days group; cT2N0: 5.4% in the fewer than 60 days group compared with 6.6% in the more than 120 days group) (p \< 0.001 for both). However, on adjusted analysis, time to operation was not significantly associated with pathologic upstaging. Patients with lobular disease and mixed histologies were more likely to be upstaged (lobular: OR 1.50; 95% CI, 1.21 to 2.53; mixed: 1.13, 95% CI, 1.08 to 1.19) compared with those with a ductal histology. Mastectomy patients in this group, as in the DCIS and NET groups, had higher odds of upstaging on final pathology (OR 2.82; 95% CI, 2.73 to 2.91). As in the NET group, those who were initially staged as having cT2 disease compared with those with cT1 disease were less likely to be upstaged (OR 0.47; 95% CI, 0.45 to 0.49).

Association between time to operation and overall survival {#sec2.2}
----------------------------------------------------------

Median follow-up time ranged from 33.7 months to 42.4 months by subgroup ([Table 4](#tbl4){ref-type="table"} ). No significant difference in OS was seen by time to operation among the ER+ (p = 0.085) and ER-- DCIS patients (p = 0.669), cT1N0 NET patients (p = 0.129), or cT2N0 NET patients (p = 0.538). In the primary operation group, a slight decrease in OS was seen in both the cT1N0 group (OS 96.7% in the fewer than 60 days to operation group vs 94.7% in the more than 120 days to operation group; p \< 0.001) and the cT2N0 group (OS was 92.6% in the fewer than 60 days to operation group vs 90.8% in the more than 120 days to operation group; p = 0.046).Table 4Cox Proportional Hazards Model Comparing 5-year Overall Survival by Disease Subtype, 2010 to 2015, According to Clinical Disease Stage and Initial Treatment StrategyVariableDCISNETPrimary operationER+ER--cT1N0cT2N0cT1N0cT2N0Median follow-up time, mo41.642.433.736.340.140.9Time to operation \< 60 d98.197.094.687.896.792.6 61--120 d97.996.897.691.895.891.8 \> 120 d97.496.696.991.594.790.8p Value timing0.0850.6690.1290.538\< 0.0010.046[^5][^6]

Association between time to operations and breast operation {#sec2.3}
-----------------------------------------------------------

Among patients with DCIS and among those with cT1-2N0 disease undergoing primary operation, mastectomy rates increased with longer time to operation (eg ER+ DCIS: 23.9% in the fewer than 60 days group vs 49.1% in the more than 120 days group; ER-- DCIS: 37.2% in the 60 or fewer days group vs 57.1% in the more than 120 days group; p \< 0.001 for both). In the NET groups, however, mastectomy rates overall decreased by time, with the clearest trend in the cT2N0 NET group (57.7% in the 60 or fewer days group vs 30.3% in the more than 120 days group; p \< 0.001) ([Fig. 3](#fig3){ref-type="fig"} ).Figure 3Breast operation type by time to operation, stratified by disease subtype and initial treatment strategy; time to operation in days. BCS, breast-conserving surgery; DCIS, ductal carcinoma in situ; ER, estrogen receptor; NET, neoadjuvant endocrine therapy.

Discussion {#sec3}
==========

Oncologic surgery triage recommendations during the COVID-19 pandemic were based on best available evidence, but admittedly, as unprecedented circumstances forced unconventional practices, some extrapolations from existing data were necessary. Questions remain about the possible effect of the proposed delay strategies on oncologic outcomes. Our study found that on adjusted analyses, surgical delays of more than 120 days were associated with pathologic upstaging in patients with DCIS but not in those with invasive disease. In DCIS patients and cT1-2N0 patients treated with NET, no survival differences were noted by time to operation.

The anxiety of nonoperative management of DCIS stems from known sampling error on core biopsy with pathologic upstaging rates ranging from 10% to 30% at the time of operation.[@bib2] ^,^ [@bib12] Although nonoperative treatment of non-high-grade DCIS is being explored in randomized clinical trials in Europe and the US (eg LORD \[Low Risk DCIS\],[@bib13] LORIS \[Low Risk DCIS\],[@bib14] and COMET \[Comparison of Operative to Monitoring and Endocrine Therapy for Low-Risk DCIS\] trials),[@bib15] these trials are enrolling highly selected patients and have yet to report their results. In addition, retrospective data have shown that in patients meeting LORIS criteria, upstage rates at the time of operation might be 7% to 20%.[@bib16] ^,^ [@bib17] The prospect of leaving patients with undiagnosed and untreated invasive disease can engender discomfort in surgeons and patients alike.

The association between pathologic upstaging and time to operation in DCIS patients has previously been studied in the NCDB, with results consistent with ours, although patients were not stratified by ER status.[@bib2] The possible mitigating effect of NET on disease progression in ER+ DCIS has been demonstrated in a small series,[@bib18] and was part of the recommended delay strategies during the pandemic. Although there were too few DCIS patients on NET to render an adequate analysis in the current study, taken together, these data suggest that initiation of NET in patients with ER+ DCIS is a reasonable delay strategy. For patients with ER-- DCIS in whom NET is not a viable option, the consequences of leaving disease in place for longer periods of time remain unclear. Our findings are similar to a previous single-institution study that demonstrated a significantly higher upgrade rate among patients with ER-- DCIS,[@bib17] although it is unclear to what extent this phenomenon is driven by grade vs ER status alone.

A previous study has suggested that longer time to operation in DCIS patients can have a small but statistically significant impact on OS.[@bib2] This is likely mediated by the increased rates of invasive disease found on excision, although a previous analysis of Surveillance, Epidemiology, and End Results program data suggests that breast cancer-specific mortality can be observed even in women who never had an invasive cancer diagnosis.[@bib19] The lack of survival difference by time to operation in our analysis might be due to short follow-up time and to the fact that we did not separate the upstaged patients from the patients with pure DCIS on final pathology. Given that the clinical question during the pandemic applied to patients in limbo between their DCIS diagnosis and surgical intervention, our finding that OS does not differ by time to operation in both ER+ and ER-- disease answers a different question than addressed by previous studies.

For patients with early-stage ER+ breast cancer, NET is not currently widely used in the US.[@bib20] ^,^ [@bib21] Similar in-breast tumor response rates have been noted in patients undergoing NET compared with those undergoing neoadjuvant chemotherapy,[@bib5] with 50% to 80% of women seeing partial or complete in-breast responses.[@bib6] ^,^ [@bib22] Although patients with cT1N0 disease were included in studies of primary endocrine therapy alone, which examined the difference in survival between older women undergoing primary endocrine therapy vs operation and endocrine therapy,[@bib8], [@bib9], [@bib10] NET has primarily been explored in patients with stage II to III disease in whom the intent was to downstage the primary tumor.[@bib5] As such, the NET population in the NCDB, especially those with clinical T1 disease included in this study, represents a highly selected group. As our multivariable analysis shows, there are specific patient characteristics (ie older age, higher Charlson Comorbidity Index score, and not having private insurance) and disease characteristics (lower grade and having a cT2 tumor compared with a cT1 tumor) that were associated with a higher likelihood of receiving NET. The bias toward older patients with more comorbidities is not surprising, as NET studies have demonstrated the possibility of favorable tumor response with a more favorable toxicity profile than chemotherapy,[@bib5] but does limit the applicability of our findings to the wider population affected by the COVID-19 surgical delays.

The lack of association between time to operation and pathologic upstaging in the NET group in our study is to be expected, given the tumor response rates reported in previous NET studies, and supports the recommendations made by the COVID-19 Pandemic Breast Cancer Consortium. The absence of a survival difference by time to operation is also consistent with the lack of difference in OS found in the primary endocrine therapy trials.[@bib8], [@bib9], [@bib10] In addition, most patients with cT2N0 disease were downstaged on final pathology. Although the absolute number of patients is small, there might be some positive, albeit unintended, effects of this particular COVID strategy.

The relationship between time to operation and pathologic upstaging in patients with invasive breast cancer has been mixed. One modeling study in pregnant patients found an association between time to operation and increased risk of positive nodes, with a 3-month delay in operation carrying an associated 2.6% increase in risk of positive lymph nodes. This has not been validated in an actual patient population.[@bib3] In a population of clinically node-negative patients with early-stage breast cancer treated at the MD Anderson Cancer Center, time to operation was not associated with pathologically positive lymph nodes on adjusted analyses.[@bib4]

Survival analyses have similarly reported mixed results, with some reporting a statistically significant association between time to operation and decreased survival,[@bib23], [@bib24], [@bib25] and others finding no such association.[@bib26], [@bib27], [@bib28] Our analysis found a slight decrease in OS (approximately 2%) at a median follow-up of 40 months in patients who underwent primary operation more than 120 days after diagnosis compared with those who underwent operation within the first 60 days. Although a survival difference might be surprising in early-stage disease, this is consistent with a Surveillance, Epidemiology, and End Results program/NCDB analysis from Bleicher and colleagues,[@bib24] which found that time to operation was associated with lower OS in patients with stage I/II disease, but not with stage III disease. Although we were able to adjust for certain patient, disease, and treatment factors, there are likely unmeasured factors underlying delays in treatment in this population, which might be responsible for the slight decrement in OS. For example, previous studies have noted that cohorts who undergo operation farther out from the time of diagnosis have higher proportions of Medicaid, uninsured, black, Hispanic, and lower-income patients.[@bib25] In addition, among a cohort of Medicaid patients in North Carolina, differences in survival by time to treatment were noted not among early-stage patients, but among late-stage patients.[@bib23] The relationship between survival and time to treatment might be significantly modified by socioeconomic and disease factors. Yet as increased time to operation during the COVID-19 pandemic was driven by different factors, the small OS difference might not hold true when outcomes of these patients are analyzed in the future.

Unmeasured factors likely also underlie the association between time to operation and the extent of breast operation. The increase in mastectomy rates by time to operation in the DCIS and primary operation groups might not be linked to extent of disease; rather it might be a factor as simple as surgical scheduling that accounts for the greater proportions of mastectomies among patients undergoing operations more than 60 days after diagnosis. Reconstruction, although not explored in our current analysis, has previously been associated with longer time to operation.[@bib4] ^,^ [@bib24] Extent of breast operations in early-stage disease is also subject to patient preference, with a variety of non-disease-related factors driving a patient's decision to undergo mastectomy.[@bib29], [@bib30], [@bib31]

Our study has several limitations. First, as mentioned previously, the applicability of our findings is limited, given that that populations experiencing delays in surgical therapy and who were selected for NET in this retrospective analysis are more select then the patients who have experienced surgical delays during the pandemic. We would assert, however, that these are the best data currently available to study the possible outcomes of oncologic surgical delays. Second, to take advantage of the most current variables in the NCDB (eg HER2 status), and given that NET use in the US has only recently begun to be more widely adopted, our analysis was limited to 2010 through 2016, rendering our follow-up time relatively short. Third, using the American Joint Committee on Cancer 8^th^ edition prognostic staging allowed us to more accurately judge rates of meaningful (ie prognostic) differences in upstaging, but the pathologic staging system does require more known data points (ie tumor grade, nodal status, HR-status, and HER-2 status). As such, not all of the patients with invasive cancer could be definitively staged pathologically. Finally, adherence to endocrine therapy cannot be assessed in the NCDB; this is a significant issue in breast cancer patients on endocrine therapy, which can influence OS.[@bib32] Due to the retrospective nature of the NCDB, however, our reported survival data likely capture a "real-world" population of adherers and nonadherers alike.

Conclusions {#sec4}
===========

In this analysis, surgical delays of more than 60 days were associated with pathologic upstaging in patients with DCIS but not in those with invasive disease. No survival differences in patients with DCIS or early-stage ER+ breast cancer on NET were noted by time to operation. Although the applicability of these data to the patients experiencing surgical delays during the COVID-19 pandemic is limited, surgeons and patients might find some reassurance in these findings, as these 2 groups represent patients significantly affected by the surgical triage recommendations of the COVID-19 Pandemic Breast Cancer Consortium. Future study of outcomes of patients treated during this time will be required to determine the actual impact of COVID-related surgical delays and delay strategies.
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Appendix {#appsec1}
========

eTable 1Univariable Analysis of Factors Associated with Upgrade by the American Joint Committee on Cancer 8^th^ Edition Prognostic StagingPatient characteristicER+ DCISER-- DCISNETPrimary operationOR (95% CI)p ValueOR (95% CI)p ValueOR (95% CI)p ValueOR (95% CI)p ValueAge 18--39 y1Ref1Ref1Ref1Ref 40--49 y0.44 (0.40--0.49)\< 0.010.67 (0.55--0.82)\< 0.010.55 (0.22--1.33)0.180.57 (0.53--0.61)\< 0.01 50--59 y0.38 (0.34--0.42)\< 0.010.45 (0.37--0.55)\< 0.010.39 (0.17--0.92)0.030.50 (0.47--0.54)\< 0.01 60--69 y0.36 (0.32--0.40)\< 0.010.35 (0.28--0.42)\< 0.010.28 (0.12--0.66)0.010.40 (0.38--0.44)\< 0.01 70--79 y0.37 (0.33--0.41)\< 0.010.32 (0.26--0.40)\< 0.010.42 (0.18--0.99)0.050.38 (0.35--0.41)\< 0.01 80+ y0.42 (0.36--0.48)\< 0.010.30 (0.23--0.39)\< 0.010.74 (0.21--1.77)0.500.56 (0.51--0.61)\< 0.01Race White1Ref1Ref1Ref1Ref Black1.05 (0.98--1.12)0.161.31 (1.15--1.49)\< 0.011.46 (0.93--2.28)0.101.48 (1.41--1.55)\< 0.01 Hispanic1.14 (1.05--1.25)\< 0.011.33 (1.13--1.57)\< 0.010.97 (0.55--1.71)0.931.28 (1.20--1.36)\< 0.01 Asian1.24 (1.12--1.37)\< 0.011.45 (1.21--1.73)\< 0.010.95 (0.43--2.07)0.901.01 (0.93--1.09)0.87Charlson Comorbidity Index 01Ref1Ref1Ref1Ref 11.10 (1.03--1.17)0.011.08 (0.96--1.22)0.200.99 (0.65--1.51)0.981.04 (1.00--1.09)0.05 21.22 (1.06--1.41)0.011.14 (0.89--1.47)0.311.39 (0.74--2.64)0.311.09 (0.99--1.20)0.05 ≥ 31.32 (1.03--1.69)0.030.95 (0.57--1.57)0.832.19 (1.02--4.70)0.041.09 (0.93--1.27)0.30Insurance Private1Ref1Ref1Ref1Ref Medicare0.89 (0.84--0.93)\< 0.010.69 (0.63--0.76)\< 0.011.36 (1.00--1.84)0.050.84 (0.82--0.87)\< 0.01 Medicaid1.18 (1.07--1.30)\< 0.011.48 (1.25--1.75)\< 0.011.77 (1.07--2.94)0.031.32 (1.24--1.40)\< 0.01 Uninsured1.13 (0.95--1.35)0.171.06 (0.78--1.44)0.720.53 (0.13--2.21)0.391.32 (1.18--1.48)\< 0.01Facility type Community1Ref1Ref1Ref1Ref Comprehensive1.26 (1.14--1.39)\< 0.011.24 (1.04--1.49)0.021.54 (0.78--3.01)0.210.99 (0.93--1.04)0.65 Academic1.40 (1.27--1.54)\< 0.011.69 (1.41--2.04)\< 0.011.68 (0.85--3.29)0.131.02 (0.96--1.08)0.56 Integrated network1.25 (1.12--1.39)\< 0.011.48 (1.21--1.80)\< 0.011.52 (0.74--3.12)0.260.96 (0.90--1.02)0.17Histology Ductal1Ref1Ref1Ref1Ref LobularNA---NA---1.66 (1.18--2.35)\< 0.011.54 (1.48--1.61)\< 0.01 Mixed0.14 (0.13--1.15)\< 0.010.08 (0.07--0.10)\< 0.011.23 (0.81--1.88)0.371.17 (1.11--1.22)\< 0.01cT cT1NA (all cTis)RefNA (all cTis)---1Ref1Ref cT2------------0.47 (0.35--0.63)\< 0.010.67 (0.64--0.70)\< 0.01Operation type BCS1Ref1Ref1Ref1Ref Mastectomy2.82 (2.70--2.95)\< 0.012.36 (2.17--2.56)\< 0.012.80 (2.11--3.72)\< 0.012.60 (2.53--2.68)\< 0.01Operation timing \< 60 d1Ref1Ref1Ref1Ref 60--120 d1.43 (1.35--1.52)\< 0.011.32 (1.19--1.47)\< 0.010.97 (0.63--1.51)0.901.21 (1.16--1.27)\< 0.01 \> 120 d1.75 (1.52--2.01)\< 0.011.70 (1.30--2.21)\< 0.011.01 (0.67--1.51)0.981.42 (1.21--1.66)\< 0.01[^7]eTable 2Multivariable Analysis of Factors Associated with Neoadjuvant Endocrine Therapy ReceiptPatient characteristicOR (95% CI)p ValueAge 18--39 y1Ref 40--49 y1.02 (0.73--1.41)0.93 50--59 y1.41 (1.02--1.93)0.04 60--69 y1.73 (1.26--2.38)\< 0.01 70--79 y1.92 (1.38--2.66)\< 0.01 80+ y2.63 (1.88--3.69)\< 0.01Race White1Ref Black1.06 (0.93--1.21)0.38 Hispanic1.35 (1.17--1.56)\< 0.01 Asian1.07 (0.88--1.30)0.50Charlson Comorbidity Index 01Ref 10.88 (0.79--0.97)0.01 21.32 (1.10--1.59)\< 0.01 ≥ 31.83 (1.41--2.39)\< 0.01Insurance Private1Ref Medicare1.16 (1.05--1.29)\< 0.01 Medicaid1.47 (1.26--1.70)\< 0.01 Uninsured1.53 (1.18--1.99)\< 0.01Region Metro1Ref Urban1.02 (0.91--1.13)0.77 Rural1.06 (0.81--1.39)0.66 Unknown1.17 (0.95--1.45)0.15Facility type Community1Ref Comprehensive1.13 (0.97--1.30)0.11 Academic1.62 (1.40--1.87)\< 0.01 Integrated Network1.59 (1.36--1.87)\< 0.01Histology Ductal1Ref Lobular1.17 (1.06--1.29)\< 0.01 Mixed1.09 (0.98--1.22)0.12Grade 11Ref 20.80 (0.74--0.87)\< 0.01 30.45 (0.40--0.51)\< 0.01cT cT11Ref cT25.40 (5.01--5.81)\<0.01[^8]
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[^1]: ALND, axillary lymph node dissection; BCS, breast-conserving surgery; DCIS, ductal carcinoma in situ; ER, estrogen receptor; NA, not applicable; NET, neoadjuvant endocrine therapy; pT, pathologic tumor category; pN, pathologic nodal category.

[^2]: p \< 0.05.

[^3]: AJCC, American Joint Committee on Cancer; DCIS, ductal carcinoma in situ; ER, estrogen receptor; NET, neoadjuvant endocrine therapy.

[^4]: BCS, breast-conserving surgery; cT, clinical tumor category, DCIS, ductal carcinoma in situ; ER, estrogen receptor; NA, not applicable; NET, neoadjuvant endocrine therapy; OR, odds ratio; Ref, reference.

[^5]: Adjusted for age, race, Charlson Comorbidity Index score, insurance, region, grade, histology, operation type, path T/N, adjuvant therapy.

[^6]: DCIS, ductal carcinoma in situ; ER, estrogen receptor; NET, neoadjuvant endocrine therapy.

[^7]: BCS, breast-conserving surgery; cT, clinical tumor category, DCIS, ductal carcinoma in situ; ER, estrogen receptor; NET, neoadjuvant endocrine therapy; OR, odds ratio; Ref, reference.

[^8]: cT, clinical tumor category; OR, odds ratio; Ref, reference.
